Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

Thu, 15 Oct 2026 07:00:00 -0400

JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update.

Conference Call and Webcast Information

Date:

Thursday, October 29, 2026

Time:

8:30 a.m. Eastern time

Conference Call:

United States (Local): +1 (585) 542-9983

United States (Toll-Free): +1 (833) 461-5787

International: Global Dial-in Numbers

Meeting

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

Thu, 15 Oct 2026 07:00:00 -0400

Conference Call and Webcast Information

Date:	Thursday, October 29, 2026

Time:	8:30 a.m. Eastern time

Conference Call:	United States (Local): +1 (585) 542-9983
	United States (Toll-Free): +1 (833) 461-5787
	International: Global Dial-in Numbers
	Meeting Form 4 LIGAND PHARMACEUTICALS For: Oct 02 Filed by: Reardon Andrew Tue, 06 Oct 2026 16:36:00 -0400 si-local-file:///var/storage/secattach/20261006/27156019.html Form 4 LIGAND PHARMACEUTICALS For: Sep 22 Filed by: Zimmermann Martine Mon, 28 Sep 2026 15:31:00 -0400 si-local-file:///var/storage/secattach/20260928/27114169.html Barclays Starts Ligand Pharma (LGND) at Overweight Fri, 25 Sep 2026 03:16:38 -0400 Barclays analyst Glen Santangelo initiates coverage on Ligand Pharma (NASDAQ: LGND) with a Overweight rating and a price target of $345.00. The analyst comments: “We initiate coverage on LGND with an Overweight rating and $345 Price Target. Ligand has undergone a transformation in recent years following a key platform divestiture and subsequent transition to pure royalty aggregation. The new business model enabled 1) higher revenue growth, 2) adj EBITDA margin expansion and 3) vast pipeline investment. While these positive developments have certainly contributed to the stock's impressive performance – +58% YTD (S&P +12%) – we believe the core fundamentals and outlook Barclays Starts Ligand Pharma (LGND) at Overweight Fri, 25 Sep 2026 03:16:38 -0400 Barclays analyst Glen Santangelo initiates coverage on Ligand Pharma (NASDAQ: LGND) with a Overweight rating and a price target of $345.00. The analyst comments: “We initiate coverage on LGND with an Overweight rating and $345 Price Target. Ligand has undergone a transformation in recent years following a key platform divestiture and subsequent transition to pure royalty aggregation. The new business model enabled 1) higher revenue growth, 2) adj EBITDA margin expansion and 3) vast pipeline investment. While these positive developments have certainly contributed to the stock's impressive performance – +58% YTD (S&P +12%) – we believe the core fundamentals and outlook Form 4 LIGAND PHARMACEUTICALS For: Sep 22 Filed by: Zimmermann Martine Thu, 24 Sep 2026 17:22:00 -0400 si-local-file:///var/storage/secattach/20260924/27102954.html Oppenheimer Reiterates Outperform Rating on Ligand Pharma (LGND) Thu, 24 Sep 2026 09:54:07 -0400 Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $334.00 price target on Ligand Pharma (NASDAQ: LGND). The analyst commented: "Ligand this morning announced a structured financing and equity investment with AvenCell Therapeutics (private). LGND gains a royalty on sales across AvenCell’s current and future pipeline of controllable allogeneic CAR-T therapies in exchange for up to $47M. The transaction is strategically consistent with LGND's royalty-aggregator model, and reinforces the company's strategy of using its balance sheet in a disciplined fashion to acquire diversified, asymmetric royalty exposure in development-stage biopharma. AvenCell’s two current programs, in early clinical development for the treatment of Form 8-K LIGAND PHARMACEUTICALS For: Sep 24 Thu, 24 Sep 2026 07:15:00 -0400 si-local-file:///var/storage/secattach/20260924/27098829.html Ligand strikes up to $47M financing deal with AvenCell Therapeutics Thu, 24 Sep 2026 07:01:43 -0400 Ligand Pharmaceuticals (Nasdaq: LGND) announced a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company, for up to $47 million to support AvenCell's pipeline of allogeneic CAR-T therapies. Under the terms of the agreement, Ligand has committed up to $41 million in exchange for a mid single-digit to low double-digit royalty on worldwide annual net sales of all current and future AvenCell pipeline assets. The applicable royalty rate will be determined based on the total amount funded. Capital will be disbursed in four tranches, with the first payable at closing and the remaining three tied to clinical milestones and Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million Thu, 24 Sep 2026 07:00:00 -0400 JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million. The investment will help advance AvenCell’s pipeline, including AVC-201 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and AVC-203 for the treatment of B-cell malignancies. Under the terms of the agreement, Ligand has committed up to $41 million in exchange for a mid single-digit to low double-digit royalty Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million Thu, 24 Sep 2026 07:00:00 -0400 JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million. The investment will help advance AvenCell’s pipeline, including AVC-201 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and AVC-203 for the treatment of B-cell malignancies. Under the terms of the agreement, Ligand has committed up to $41 million in exchange for a mid single-digit to low double-digit royalty Citi raises Ligand Pharma price target to $397 after royalty deal Wed, 23 Sep 2026 06:16:47 -0400 Citi analyst Yigal Nochomovitz raised the price target on Ligand Pharmaceuticals (NASDAQ: LGND) to $397 from $390, while maintaining a Buy rating. The adjustment follows Ligand's acquisition of a royalty interest in Ryjunea, a myopia eye drop developed by Sydnexis, for $23 million upfront. Under the deal, Ligand will receive a tiered royalty ranging from low-double-digit to high-teens percentages on Ryjunea sales in the EMEA region, along with undisclosed milestone payments, through Sydnexis's existing license agreement with Santen Pharma. Santen has guided to global sales of approximately 30 billion yen for fiscal year 2029 and peak sales of approximately 60 billion yen, Sydnexis sells EMEA royalty rights to Ligand for $23 million Tue, 22 Sep 2026 09:05:01 -0400 Sydnexis, Inc. has agreed to sell its royalty rights for Ryjunea® in Europe, the Middle East, and Africa to Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) for $23 million upfront, according to a press release from the company. Under the terms of the deal, Ligand acquires a 100% interest in certain payments and related rights under Sydnexis' existing license agreement with Santen S.A., which markets the product as Ryjunea® in the European Union and the United Kingdom. Sydnexis retains all rights to SYD-101 in the United States and all other non-Santen licensed territories. SYD-101 is a low-dose atropine formulation intended to treat pediatric progressive Sydnexis sells EMEA royalty rights to Ligand for $23 million Tue, 22 Sep 2026 09:05:01 -0400 Sydnexis, Inc. has agreed to sell its royalty rights for Ryjunea® in Europe, the Middle East, and Africa to Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) for $23 million upfront, according to a press release from the company. Under the terms of the deal, Ligand acquires a 100% interest in certain payments and related rights under Sydnexis' existing license agreement with Santen S.A., which markets the product as Ryjunea® in the European Union and the United Kingdom. Sydnexis retains all rights to SYD-101 in the United States and all other non-Santen licensed territories. SYD-101 is a low-dose atropine formulation intended to treat pediatric progressive Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® Tue, 22 Sep 2026 09:02:00 -0400 $23 million upfront payment immediately monetizes future royalties associated with Ryjunea in Europe, the Middle East, and Africa Capital further strengthens Sydnexis’ balance sheet as Company continues to advance SYD-101 through U.S. regulatory process and prepares for potential commercialization in 2027 DEL MAR, Calif.--(BUSINESS WIRE)-- Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to sell its royalty rights associated with net sales of Ryjunea® in Europe, the Middle East, and Africa (EMEA). Under the terms of the Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® Tue, 22 Sep 2026 09:02:00 -0400 $23 million upfront payment immediately monetizes future royalties associated with Ryjunea in Europe, the Middle East, and Africa Capital further strengthens Sydnexis’ balance sheet as Company continues to advance SYD-101 through U.S. regulatory process and prepares for potential commercialization in 2027 DEL MAR, Calif.--(BUSINESS WIRE)-- Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to sell its royalty rights associated with net sales of Ryjunea® in Europe, the Middle East, and Africa (EMEA). Under the terms of the Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners Tue, 22 Sep 2026 09:00:00 -0400 SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital. In conjunction with the financing, James Gale, Founding Partner and Managing Director of Signet, has joined Primrose's Board of Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners Tue, 22 Sep 2026 09:00:00 -0400 SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital. In conjunction with the financing, James Gale, Founding Partner and Managing Director of Signet, has joined Primrose's Board of Form 8-K LIGAND PHARMACEUTICALS For: Sep 22 Tue, 22 Sep 2026 07:08:00 -0400 si-local-file:///var/storage/secattach/20260922/27087466.html Ligand pays $23M for royalty stake in pediatric myopia drug Ryjunea Tue, 22 Sep 2026 07:00:45 -0400 Ligand Pharmaceuticals (Nasdaq: LGND) has acquired a royalty and milestone interest in Ryjunea, a pediatric myopia treatment marketed by Santen Pharmaceutical, from Sydnexis for $23 million upfront, according to a company statement. Under the agreement, Ligand obtains a 100% interest in certain payment rights under Sydnexis's existing license agreement with Santen, including a tiered royalty ranging from low-double-digit to high-teens percentages on Ryjunea net sales in Europe, the Middle East, and Africa, as well as certain milestone payments. Sydnexis retains commercial rights to Ryjunea in the U.S. and other non-Santen licensed territories. Ryjunea is a once-nightly, low-dose atropine eye drop using a Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million Tue, 22 Sep 2026 07:00:00 -0400 Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.’s (“Santen”) Ryjunea® from Sydnexis, Inc. (“Sydnexis”) for a $23 million upfront payment. Ryjunea is a once-nightly, low-dose atropine eye drop Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million Tue, 22 Sep 2026 07:00:00 -0400 Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.’s (“Santen”) Ryjunea® from Sydnexis, Inc. (“Sydnexis”) for a $23 million upfront payment. Ryjunea is a once-nightly, low-dose atropine eye drop Form 4 LIGAND PHARMACEUTICALS For: Sep 10 Filed by: Zimmermann Martine Mon, 14 Sep 2026 16:59:00 -0400 si-local-file:///var/storage/secattach/20260914/27059128.html Form 144 LIGAND PHARMACEUTICALS Filed by: Zimmermann Martine Thu, 10 Sep 2026 16:01:00 -0400 si-local-file:///var/storage/secattach/20260910/27048272.html

StreetInsider.com News Articles

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

Form 4 LIGAND PHARMACEUTICALS For: Oct 02 Filed by: Reardon Andrew

Form 4 LIGAND PHARMACEUTICALS For: Sep 22 Filed by: Zimmermann Martine

Barclays Starts Ligand Pharma (LGND) at Overweight

Barclays Starts Ligand Pharma (LGND) at Overweight

Form 4 LIGAND PHARMACEUTICALS For: Sep 22 Filed by: Zimmermann Martine

Oppenheimer Reiterates Outperform Rating on Ligand Pharma (LGND)

Form 8-K LIGAND PHARMACEUTICALS For: Sep 24

Ligand strikes up to $47M financing deal with AvenCell Therapeutics

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Citi raises Ligand Pharma price target to $397 after royalty deal

Sydnexis sells EMEA royalty rights to Ligand for $23 million

Sydnexis sells EMEA royalty rights to Ligand for $23 million

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Form 8-K LIGAND PHARMACEUTICALS For: Sep 22

Ligand pays $23M for royalty stake in pediatric myopia drug Ryjunea

Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million

Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million

Form 4 LIGAND PHARMACEUTICALS For: Sep 10 Filed by: Zimmermann Martine

Form 144 LIGAND PHARMACEUTICALS Filed by: Zimmermann Martine